• Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
REVIEW
Year : 2015  |  Volume : 1  |  Issue : 2  |  Page : 43-49

Review of Cancer Immunotherapy: Application of Chimeric Antigen Receptor T Cells and Programmed Death 1/Programmed Death-ligand 1 Antibodies


1 Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China; Department of Hematology and Oncology, Harvard Medical School, Boston, MA, USA
2 Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
3 Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan; Engineering Key Laboratory for Cell Therapy of Henan Province, Zhengzhou, Henan; School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China

Correspondence Address:
Prof. Yi Zhang
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, No. 1, Jianshe Road, Zhengzhou 450052, Henan
China
Login to access the Email id

Source of Support: This work was supported by grants from National Natural Science Foundation of China (Grant No. 31400752 and 81271815) and the Basic and Advanced Technology Research Foundation from Science and Technology Department of Henan Province (Grant No. 201403067, Conflict of Interest: None


DOI: 10.4103/2395-3977.155923

Rights and Permissions

Cancer immunotherapy strategies based on chimeric antigen receptor (CAR) transduced T cells or antibodies against immune checkpoints, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1), achieved significant successes from bench to clinic in the past 2 years. CARs are artificial engineered receptors that can specifically target tumor cell surface antigen, activate T cell and further enhance T cell function, independent of major histocompatibility complex. CAR T cells have shown promising outcomes in cancers, especially in hematologic malignancies. CTLA-4 and PD-1 are two important immune checkpoints negatively regulating T cell activation. Clinical benefits of CTLA-4/PD-1 antibodies are significant in melanoma and other solid tumors. PD-1 is predicted to have fewer side effects and greater antitumor activity than CTLA-4. In this review, we will summarize current immunotherapies based on CAR T cells and PD-1.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3856    
    Printed107    
    Emailed0    
    PDF Downloaded680    
    Comments [Add]    

Recommend this journal